Introduction {#sec1}
============

Hepatocellular carcinoma (HCC) is a commonly diagnosed malignancy and the leading cause of cancer death worldwide and it has shown an increasing incidence compared to that of other cancers.[@bib1], [@bib2], [@bib3] Although improvements have been made in surgical and therapeutic techniques, the 5-year survival rate of HCC patients is still unsatisfactory. The molecular mechanisms underlying liver cancer pathology need to be further explored.

Long noncoding RNAs (lncRNAs) are a type of RNAs that are longer than 200 nt and traditionally defined as not having translation potential; however, recent studies have shown that some lncRNAs could produce short functional peptides.[@bib4]^,^[@bib5] An increasing number of studies have verified that lncRNAs play a large role in biological processes. Some lncRNAs function as coregulators of proteins that directly combine with coregulator proteins to regulate downstream tumor-related gene expression.[@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12] Furthermore, another class of lncRNAs functions as competing endogenous RNAs (ceRNAs).[@bib13], [@bib14], [@bib15] This class of lncRNAs sequesters microRNAs by acting as a sponge and controls the expression of microRNA-targeted oncogenes or tumor repressors. A well-studied lncRNA, lncRNA-ATB, inducesepithelial-mesenchymal transition (EMT) and the invasion of cancer cells through upregulating ZEB1 and ZEB2 expression by acting as a ceRNA for miR-200.[@bib13] In addition, the tumorigenic lncRNA HULC also functions as a ceRNA through sequestering miR-372, resulting in the upregulation of an oncogene in liver cancer.[@bib14] These findings revealed that the aberrant expression of lncRNAs plays a role in cell proliferation, angiogenesis, and tumor development. The identification of novel lncRNAs and the exploration of their functions and regulatory molecular mechanisms could provide promising therapeutic targets for liver cancer.

In our previous study, a novel rat lncRNA, *lnc-HC*, was identified in rat hepatocytes as a regulator of hepatocyte cholesterol catabolism.[@bib16]^,^[@bib17] Mechanistically, *lnc-HC* and its coregulator hnRNPA2B1 form the lncRNA-protein complex and decrease the stability of mRNAs encoding *Cyp7a1* and Abca1, which are critical enzymes that contribute to cholesterol catabolism. Furthermore, we decided to identify the human homolog of *lnc-HC* and explore its role in biological processes of the human body. In the current study, a novel human lncRNA was identified, named *LNC-HC*. Interestingly, human *LNC-HC* is remarkably decreased in HCC tumor tissues. *LNC-HC* inhibits HCC cell proliferation both *in vitro* and *in vivo*. Mechanistically, *LNC-HC* upregulates the expression of tumor repressors by functioning as a ceRNA to sequester *hsa-miR-183-5p*. Our findings suggest that *LNC-HC* could be regarded as a novel biomarker of HCC and could provide a novel therapeutic target for HCC treatment.

Results {#sec2}
=======

Identification of the Novel Human lncRNA *LNC-HC* {#sec2.1}
-------------------------------------------------

Previously, we identified a lncRNA in rat liver, *lnc-HC*, that plays a role in fine-tuning hepatic cholesterol and fatty acid metabolism.[@bib16]^,^[@bib17] Since then, we further identified the human homolog of *lnc-HC*, *LNC-HC* (GenBank: MN026163). A 1,226-nt fragment of *LNC-HC* was first identified by a BLAST (Basic Local Alignment Search Tool) search in the UCSC (University of California Santa Cruz) database with the homologous rat *lnc-HC* gene sequence, and *LNC-HC* was found to be located on chromosome 13 ([Figure 1](#fig1){ref-type="fig"}A). The full-length sequence of human *LNC-HC* was confirmed to be 1,063 nt in length by SMART RACE technology ([Figure 1](#fig1){ref-type="fig"}B; [Table S1](#mmc1){ref-type="supplementary-material"}). *LNC-HC* overlaps with the 3′ UTR of protein-encoding gene *SLC25A15.* In accordance, northern blotting detected two clear transcripts (1,063 and 3,821 nt) with *LNC-HC*-probe and one transcript (3,821 nt) with *SLC25A15*-probe ([Figure 1](#fig1){ref-type="fig"}C). These results confirmed that *LNC-HC* is a real transcript and is overlapping with the 3′ UTR of *SLC25A15*.Figure 1Identification of *LNC-HC* as a Novel Human lncRNA(A) Location of *LNC-HC* in the human genome. (B) The PCR products obtained from 3′-RACE (left panel) and 5′-RACE (right panel). Lane M, DL2000 DNA marker. (C) Northern blotting identification of *LNC-HC* as a novel transcript and expressed differentially from overlapping gene *SLC25A15*. (D) Predicted ORFs of *LNC-HC* by ORF Finder (<https://www.ncbi.nlm.nih.gov/orffinder/>). (E) The predicted ORFs of *LNC-HC*, the full length of *lnc-DC*, and the first exon of *ACTB* were cloned into pcDNA3.1+ with C-terminal FLAG/EGFP (upper panel). Immunoblotting of FLAG-fusion protein in LO2 cells transfected with the recombinant plasmids, taking GAPDH as the loading control (lower panel). (F) Fluorescence microscopic images of the EGFP-fusion protein expression.

To determine the protein coding potential of *LNC-HC*, we performed informatics analysis and protein expression experiments. First, the predicted open reading frames (ORFs) of *LNC-HC* are short and did not show any conserved protein domains among various species ([Figure 1](#fig1){ref-type="fig"}D; [Table S2](#mmc1){ref-type="supplementary-material"}). Second, there was no protein coding potential as determined by the coding potential calculator (<http://cpc2.cbi.pku.edu.cn/>). Experimentally, we cloned the three ORFs of *LNC-HC* predicted with sense strand into the pcDNA3.1+ vector with a C-terminal FLAG or EGFP tag ([Figures 1](#fig1){ref-type="fig"}E and [S1](#mmc1){ref-type="supplementary-material"}). *ACTB* is a control of the protein-coding gene and *lnc-DC* is a control of lncRNA. Immunoblotting results showed that FLAG-tag protein was hardly detected in the *LNC-HC* group ([Figure 1](#fig1){ref-type="fig"}E, lower panel). EGFP-fusion protein showed the similar results ([Figure 1](#fig1){ref-type="fig"}F). Based on bioinformatics analysis and protein expression experiments, we confirmed that *LNC-HC* is a lncRNA and is the human homolog of the previously identified rat *lnc-HC.*

*LNC-HC* Is Decreased in Hepatic Tumors in HCC {#sec2.2}
----------------------------------------------

Quantitative real-time PCR results showed that *LNC-HC* was significantly decreased in three types of HCC cell lines, including Huh7, Hep3B and Skhep1, compared with the human hepatocyte cell line LO2; *SLC25A15* showed no differences among these groups of cells ([Figure 2](#fig2){ref-type="fig"}A). In addition, there was no significant correlation between *LNC-HC* and *SLC25A15* expression in these four cell lines ([Figure 2](#fig2){ref-type="fig"}B). Among the 20 hepatic tumor tissues, the paired 20 adjacent non-tumor tissues and 10 normal liver tissues from 20 patients with HCC, *LNC-HC* was significantly decreased in the tumor tissues compared with the adjacent and normal liver tissues; *SLC25A15* showed a similar expression pattern ([Figure 2](#fig2){ref-type="fig"}C). To check the correlation of the expression between *LNC-HC* and *SLC25A15* in clinical samples, a detailed analysis was performed. The two genes expressions were significantly correlated in adjacent tissues; however, no correlation was observed in tumor tissues and normal ones ([Figure 2](#fig2){ref-type="fig"}D). According to the median ratio of *LNC-HC* expression, HCC patients were divided into *LNC-HC*^low^ and *LNC-HC*^high^ groups. Clinicopathological analysis suggested that *LNC-HC* expression was more likely correlated with tumor size (p = 0.1409) and tumor-node-metastasis (TNM) stage (p = 0.075) as compared with other parameters, including age, sex, metastasis, carcinoembryonic antigen (CEA), and alpha-fetoprotein (AFP) levels ([Table 1](#tbl1){ref-type="table"}). These findings suggest that *LNC-HC* might be a potential tumor suppressor in HCC.Figure 2*LNC-HC* Expression Was Significantly Reduced in Both HCC Cell Lines and Clinical Hepatic Tumor Tissues(A) Quantitative real-time PCR detection of *LNC-HC* and *SLC25A15* mRNA levels in the human hepatocyte cell line LO2 and the HCC cell lines Huh7, Hep3B, and Skhep1. (B) Correlation analysis of *LNC-HC* and *SLC25A15* expression in four types of cell lines at the mRNA level. (C) Quantitative real-time PCR detection of *LNC-HC* and *SLC25A15* expression in 20 hepatic tumor tissues, 20 paired adjacent non-tumor tissues, and 10 paired normal tissues from HCC patients. (D) Correlation analysis of *LNC-HC* and *SLC25A15* expression in clinical liver samples at the mRNA level. Ad, adjacent non-tumor tissues. *ACTB* was used for normalization in the quantitative real-time PCR assay. ∗p \< 0.05, ∗∗p \< 0.01. n.s., not significant. Values are expressed as the means ± SEM.Table 1The Association between *LNC-HC* Expression and Clinicopathological Characteristics of the 20 HCC PatientsVariableAll Patients (n)*LNC-HC* Expressionp ValueLowHighAll cases201010**Age (years)** 1587\>0.9999 ≥60523**Sex** Male1688\>0.9999 Female422**Tumor size (cm)** 6150.1409 ≥51495**TNM stage** I2110.075 II404 III1275 IV220**Lymphatic metastasis** Yes211\>0.9999 No1899**Distant metastasis** Yes211\>0.9999 No1899**CEA (ng/mL)** 13580.3498 ≥5752**AFP (ng/mL)** 10460.6563 ≥4001064[^1]

*LNC-HC* Inhibits Cell Proliferation *In Vitro* {#sec2.3}
-----------------------------------------------

To test the biological effects of *LNC-HC* on cell growth, *LNC-HC* and *SLC25A15* were overexpressed in Huh7 and LO2 cells to generate ^overLNC-HC^Huh7/LO2 and ^overSLC25A15^Huh7/LO2 cells, respectively ([Figures 3](#fig3){ref-type="fig"}A and 3B). An MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide) assay showed that *LNC-HC* overexpression significantly inhibited the proliferation of Huh7 cells *in vitro* compared with overexpressed negative control (NC) cells; *SLC25A15* overexpression had no effect ([Figure 3](#fig3){ref-type="fig"}C). Moreover, the overexpression of *LNC-HC* and *SLC25A15* did not affect the growth of LO2 cells within 72 h ([Figure 3](#fig3){ref-type="fig"}D). Consistently, *LNC-HC* overexpression suppressed Huh7 and LO2 cell colony formation ([Figures 3](#fig3){ref-type="fig"}E and 3F). A wound healing study showed that *LNC-HC* inhibited the migration of Huh7 and LO2 cells ([Figure 3](#fig3){ref-type="fig"}G). These results indicated that *LNC-HC* suppresses Huh7 cell growth *in vitro*.Figure 3*LNC-HC* Suppressed Cell Proliferation and Migration(A) Quantitative real-time PCR detection of *LNC-HC* and *SLC25A15* expression in *LNC-HC* or *SLC25A15* stably overexpressing Huh7 cells. (B) Quantitative real-time PCR detection of *LNC-HC* and *SLC25A15* in the indicated stably overexpressing LO2 cells. (C) MTT assay measurement of the proliferation of the indicated Huh7 cells at different time points (0, 24, 48, and 72 h). (D) MTT measurement of the proliferation of LO2 cells at different time points (0, 24, 48, and 72 h). (E) Colony formation of ^overNC^Huh7 and ^overLNC-HC^Huh7 cells (left) and quantification histogram (right). (F) Colony formation of ^overNC^LO2 and ^overLNC-HC^LO2 cells (left) and quantification histogram (right). (G) Detection of the migration of ^overNC^Huh7/LO2 and ^overLNC-HC^Huh7/LO2 cells by using a wound healing assay (up) and quantification histogram (low). *ACTB* was utilized for normalization in the quantitative real-time PCR. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001. Values are expressed as the means ± SEM.

*LNC-HC* Inhibits Tumor Growth in a Mouse Xenograft Model {#sec2.4}
---------------------------------------------------------

To check the effect of *LNC-HC* on tumor growth *in vivo*, we generated a xenograft tumor model by subcutaneously injecting ^overNC^Huh7 and ^overLNC-HC^Huh7 cells into BALB/c nude mice. Compared with ^overNC^Huh7 cells, ^overLNC-HC^Huh7 cells grew more slowly, as indicated by their smaller tumor volumes ([Figures 4](#fig4){ref-type="fig"}A--4C) and tumor weights ([Figure 4](#fig4){ref-type="fig"}D). These results showed that *LNC-HC* significantly -suppresses tumor growth *in vivo*.Figure 4*LNC-HC* Inhibited Tumor Growth in a Xenograft Mouse Model(A) BALB/c nude mice (aged 4 weeks, male, n = 6) were subcutaneously injected with 5 × 10^6\ overNC^Huh7 (left side) or ^overLNC-HC^Huh7 cells (right side) per mouse. (B) Tumor volumes were measured every 5 days from day 5 to day 45. On day 45, the mice were sacrificed. (C and D) The tumors from model mice were collected (C) and weighed (D). ∗p \< 0.05, ∗∗∗p \< 0.001. Values are expressed as the means ± SEM.

LNC-HC Interacts with *hsa-miR-183-5p* {#sec2.5}
--------------------------------------

To determine the regulatory mechanism involved in the effects of *LNC-HC* on the antitumor process, we first examined the possibility of a ceRNA-like pattern. In the prediction of the interaction between microRNAs and *LNC-HC* by the miRDB software (<http://mirdb.org/>), six microRNA candidates with higher scores were obtained, including *hsa-miR-183-5p*, -*4482*, -*10527*, -*4276*, -*5001*, and *-146a*. Quantitative real-time PCR results suggested that *hsa-miR-183-5p* (hereafter referred to as *miR-183*) was significantly increased in tumor tissues compared with adjacent and normal tissues, while *miR-4482* and *miR-10527* expression were decreased in tumors compared with adjacent tissues ([Figure 5](#fig5){ref-type="fig"}A). Among the six candidates, *miR-183* expression in tumor tissues indicated that it might interact with *LNC-HC* to form a ceRNA regulatory system. *In vitro* experiments showed that the *miR-183* mimic significantly decreased *LNC-HC* expression both in Huh7 and LO2 cells ([Figures 5](#fig5){ref-type="fig"}B and 5C), whereas *LNC-HC* had no effect on *miR-183* expression ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). In addition, the *miR-183* mimic facilitated Huh7 and LO2 cell proliferation; *miR-183* inhibited the suppression by *LNC-HC* of the proliferation of Huh7 cells ([Figure 5](#fig5){ref-type="fig"}D). To verify the direct interaction between *miR-183* and *LNC-HC*, we constructed dual-luciferase reporter gene vectors that contained wild-type and mutant *miR-183*-targeted *LNC-HC* sequences (1 and 2) using pmirGLO as a basic plasmid, which are referred to as pLNC-HC1-wt/mut and pLNC-HC2-wt/mut, respectively ([Figure 5](#fig5){ref-type="fig"}E). After the transfection of pLNC-HC1/2-wt/mut and the *miR-183* mimic, we found that *miR-183* decreased the luciferase activity of pLNC-HC1-wt and pLNC-HC2-wt but had no effect on the mutant plasmids in both Huh7 and LO2 cells ([Figures 5](#fig5){ref-type="fig"}F and 5G). These findings suggested that *miR-183* directly targets *LNC-HC* through binding regions 1 and 2; the two genes, a lncRNA and a microRNA, may form a ceRNA system to coregulate downstream gene expression.Figure 5*miR-183* Directly Interacted with *LNC-HC*(A) Quantitative real-time PCR detection of the expression of the indicated microRNAs in hepatic tumor samples. (B) Quantitative real-time PCR detection of *miR-183* and *LNC-HC* expression in Huh7 cells transfected with the negative control mimic (NC, 50 nM) or *miR-183* mimic (*miR-183*, 50 nM) for 24 h. (C) Quantitative real-time PCR detection of *miR-183* and *LNC-HC* expression in LO2 cells transfected with the NC mimic (50 nM) or *miR-183* mimic (50 nM) for 24 h. (D) MTT assay of the cell proliferation under *LNC-HC* or *miR-183* overexpression. (E) Schematic diagram of wild-type and site-directed mutant of the *miR-183* binding sites 1 and 2 within the *LNC-HC* sequence. (F) Dual-luciferase reporter gene assay of the Huh7 cells cotransfected with pLNC-HC1/2-WT/mut and NC/*miR-183* mimic. (G) Luciferase activity of LO2 cells cotransfected with pLNC-HC1/2-WT/mut and NC/*miR-183* mimic. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001. Values are expressed as the means ± SEM.

*LNC-HC/miR-183* Coregulate the Expression of Tumor Repressors as ceRNA {#sec2.6}
-----------------------------------------------------------------------

To verify the ceRNA function of *LNC-HC* and *miR-183*, we predicted 16 tumor repressors that were directly targeted by *miR-183* using miRDB software. Among these candidates, 6 genes (*AKAP12*,[@bib18], [@bib19], [@bib20] *FOXO1*,[@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33], [@bib34] *IDH2*,[@bib35], [@bib36], [@bib37] *PDCD4*,[@bib38], [@bib39], [@bib40], [@bib41], [@bib42], [@bib43], [@bib44], [@bib45], [@bib46] *PTEN*,[@bib47]^,^[@bib48] and *SOCS6*[@bib35]^,^[@bib49]) have previously been reported as *miR-183* targets; the other 10 genes (*ARHGDIA*, *CRKL*, *DDIT4*, *DYRK2*, *FOXN3*, *LATS2*, *PTPN12*, *RHOB*, *SMG-1*, and *SPRED1*) were the predicted candidates with the highest scores without experimental verification. In Huh7 cells, four of the verified genes (including *AKAP12*, *FOXO1*, *IDH2*, and *PDCD4*) and six of the predicted genes (including *CRKL*, *DDIT4*, *FOXN3*, *LATS2*, *PTPN12*, and *SMG-1*) were significantly suppressed by *miR-183* ([Figures 6](#fig6){ref-type="fig"}A and 6B). In LO2 cells, five of the verified genes (including *AKAP12*, *FOXO1*, *IDH2*, *PDCD4*, and *SOCS6*) and four of the predicted genes (including *DDIT4*, *DYRK2*, *LATS2*, and *SPRED1*) were suppressed by *miR-183* ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). Next, we examined the effect of *LNC-HC* on the expression of these candidate genes. In Huh7 cells, *LNC-HC* overexpression increased the expression of four genes both at the mRNA and protein levels, including *AKAP12*, *FOXN3*, *FOXO1*, and *LATS2* ([Figures 6](#fig6){ref-type="fig"}C and 6D). In contrast, *LNC-HC* knockdown decreased the expression of these genes ([Figures 6](#fig6){ref-type="fig"}E and 6F). In LO2 cells, *LNC-HC* increased four genes, including *AKAP12*, *DYRK2*, *FOXO1*, and *LATS2* ([Figures S3](#mmc1){ref-type="supplementary-material"}C and S3D), while *LNC-HC* knockdown decreased these four genes ([Figures S3](#mmc1){ref-type="supplementary-material"}E and S3F). To further elucidate the ceRNA regulation, we overexpressed *miR-183* and *LNC-HC* expression in cells. The results showed that *LNC-HC* could completely rescue the suppressive effect of *miR-183* on expression of the four genes Huh7 cells, including *AKAP12*, *FOXN3*, *FOXO1*, and *LATS2* ([Figures 6](#fig6){ref-type="fig"}G and 6H). Meanwhile, the expressions of four genes, including *AKAP12*, *DYRK2*, *FOXO1*, and *LATS2*, were rescued by *LNC-HC* overexpression in LO2 cells ([Figures S3](#mmc1){ref-type="supplementary-material"}G and S3H).Figure 6*LNC-HC* and *miR-183* Coregulated Downstream Tumor Repressor Expression as a ceRNA Pattern(A and B) Quantitative real-time PCR analysis of indicated expression of genes in NC/*miR-183* mimic-transfected Huh7 cells. (A) Genes already verified as *miR-183* targets. (B) Genes predicted to be targets of *miR-183*. (C) Quantitative real-time PCR detection of gene expression in ^overLNC-HC^Huh7 and ^overSLC25A15^Huh7 cells. (D) Western blotting analysis of the indicated gene expression in ^overLNC-HC^Huh7 and ^overSLC25A15^Huh7 cells (left) and quantification histograms (right). (E) Quantitative real-time PCR detection of *miR-183*-targeted gene expression in *LNC-HC* or *SLC25A15* knockdown Huh7 cells. (F) Western blotting analysis of indicated gene expression in *LNC-HC* or *SLC25A15* knockdown Huh7 cells (left) and quantification histogram (right). (G) Quantitative real-time PCR detection of indicated genes in Huh7 cells transfected with NC/*miR-183* mimic and pcDNA3.1+/pcLNC-HC for 24 h. (H) Western blotting analysis of indicated gene expression in Huh7 cells transfected with NC/*miR-183* mimic and pcDNA3.1+/pcLNC-HC (left) and quantification histogram (right). (I) Quantitative real-time PCR detection of *LNC-HC*-targeted genes in hepatic tumor samples. (J) Kaplan-Meier plots of median overall survival data for patients with liver cancer (n = 364) by using Kaplan-Meier Plotter. Western blotting shows one representative result and quantitative data from three independent experiments. ACTB was the loading control in the western blotting assay. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001. Values are expressed as the means ± SEM.

To further check the effect of *LNC-HC* and *miR-183* target genes on Huh7 cell proliferation, an MTT assay and colony formation and wound healing experiments were performed under the condition of *LNC-HC* overexpression and knockdown of indicated genes, including *AKAP12*, *FOXN3*, *FOXO1*, and *LATS2*. Each gene could be significantly knocked down by small interfering RNAs (siRNAs) ([Figure S4](#mmc1){ref-type="supplementary-material"}A). MTT results showed that knockdown of *FOXN3* and *LATS2* could significantly counteract the suppression effect of *LNC-HC* on the proliferation of Huh7 cells; knockdown of *AKAP12* and *FOXO1* has no obvious effect on that within 96 h ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Similarly, knockdown of *FOXN3* and *LATS2* increased the number of colony formations as compared with the *LNC-HC* overexpression group ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). A wound healing assay suggested that only *FOXN3* knockdown strongly suppressed the metastasis of Huh7 cells under *LNC-HC* overexpression, while the other three genes showed no obvious effect within 96 h ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B). These results doubly confirmed that *LNC-HC* suppresses HCC cell proliferation; in addition, they suggested the critical roles of *LNC-HC/miR-183/FOXN3* and *LATS2* pathways on cell proliferation.

To verify the association between *LNC-HC* and its target genes, we further checked their expressions in hepatic tissues from HCC patients. These genes were all significantly decreased in tumors compared to those in adjacent tissues ([Figures 6](#fig6){ref-type="fig"}I and [S7](#mmc1){ref-type="supplementary-material"}A). The Kaplan-Meier analysis showed that high mRNA level of *AKAP12*, *FOXN3*, *FOXO1*, and *LATS2* associated with better patients median overall survival in patients with liver cancer ([Figure 6](#fig6){ref-type="fig"}J); however, a high level of DYRK2 mRNA indicated poor patient survival ([Figure S7](#mmc1){ref-type="supplementary-material"}B). With regard to the correlation between the expression of *LNC-HC* and its target genes, three genes (*AKAP12*, *FOXN3*, and *LATS2*) were significantly correlated with *LNC-HC* in hepatic tumors; only *LATS2* was significantly correlated with *LNC-HC* both in tumor and in adjacent tissues. *AKAP12* and *LATS2* showed a significant correlation with *LNC-HC* in all samples containing tumor, adjacent tissues, and normal tissues ([Table 2](#tbl2){ref-type="table"}). These findings verified that *LNC-HC* and *miR-183* regulate downstream tumor repressors through a ceRNA pattern both *in vitro* and *in vivo*.Table 2Correlation between *LNC-HC* and Target Genes in Hepatic Tumors from Patients with HCCGeneCorrelation Analysis between *LNC-HC* and Target Genes ExpressionTumorAdjacentNormalAll Samplesr Valuep Valuer Valuep Valuer Valuep Valuer Valuep Value*AKAP12*0.58890.0063**∗∗**0.22080.34950.16340.65200.3850.0058**∗∗***DYRK2*0.37740.1009−0.03380.88750.58230.07740.23570.0995*FOXN3*0.50450.0233**∗**−0.03610.87980.41520.23280.18220.2054*FOXO1*0.26040.26750.20170.3939−0.54750.10140.2760.0524*LATS2*0.53760.0145**∗**0.52780.0168**∗**0.00130.99720.51210.0001∗∗∗[^2]

Discussion {#sec3}
==========

In the current study, we identified a novel human lncRNA, *LNC-HC*, that is the human homolog of rat *lnc-HC*. We verified its function as an inhibitor of HCC cell growth *in vitro* and its role as a tumor suppressor *in vivo*. Mechanistically, *LNC-HC* upregulates the expression of a cluster of tumor repressors, including *AKAP12*, *DYRK2*, *FOXN3*, *FOXO1*, and *LATS2*, by sequestering *miR-183* as a ceRNA.

*LNC-HC* is the human homolog of rat *lnc-HC* and possesses a high degree of synteny, indicating it has a good conservation. SMART RACE and northern blotting confirmed that *LNC-HC* is a novel transcript of 1,063 nt. Both bioinformatics analysis and FLAG/EGFP-tag fusion protein expression indicated that *LNC-HC* has no protein coding potential. These results confirmed that LNC-HC functions as a lncRNA.

We further explored the function of human *LNC-HC* in HCC development. *LNC-HC* is significantly decreased in HCC hepatic tumors as well as in three types of HCC cell lines, including Huh7, Hep3B, and Skhep1. The mRNA expression of *SLC25A15*, a protein-encoding gene that overlaps with *LNC-HC*, was likewise significantly decreased in tumor tissues. However, expression of the two genes demonstrated a lack of correlation in HCC cells and HCC tumors, suggesting their independent expression patterns under these two conditions and different pathways in modulating cancer pathology; in addition, the two genes showed strong correlation in adjacent tissues, suggesting their potential cooperation in regulating tumorigenesis and indicating the aberrant gene profile presented in adjacent tissues. Although there is no significance regarding the correlation between *LNC-HC* expression and clinicopathological characteristics (p \> 0.05), a low level of *LNC-HC* was clearly correlated with TNM stage and tumor size to a certain extent. The correlation tends to be significant with a bigger sample size. We further focused on *LNC-HC* by excluding the effects of *SLC25A15*. We constructed *LNC-HC*-overexpressing stable cells and utilized *SLC25A15* overexpression as a control. The MTT assay showed that ^overLNC-HC^Huh7 cells showed a slower proliferation rate over 72 h compared with ^overNC^Huh7 and ^overSLC25A15^Huh7 cells; however, no detectable change in proliferation was identified in LO2 cells. This might be because LO2 cells are a normal hepatocyte cell line with an increased baseline of *LNC-HC* level and thus have a normal proliferation rate. Nonetheless, during a longer cultivation, the growth difference between ^overNC^LO2 and ^overLNC-HC^LO2 cells was much more obvious, as indicated by the colony formation assay. In addition to the *in vitro* evidence, an *in vivo* mouse model further established the antitumor effect of *LNC-HC*.

The ceRNA hypothesis was proposed by Salmena et al.[@bib50] in 2011. Several lines of evidence in this field have shown the role of ceRNA in the fine-tuning of regulatory pathways; nonetheless, only a few studies have reported the role of ceRNAs in liver cancer pathology.[@bib51], [@bib52], [@bib53], [@bib54], [@bib55], [@bib56] A full understanding of the ceRNAs involved in HCC, including those formed by lncRNAs and microRNAs, could provide new insights and new therapeutic targets for HCC. In our study, *miR-183* was identified as the coregulator of *LNC-HC*. In agreement with previous studies, *miR-183* expression was dramatically increased in HCC tumor tissues and is considered an oncomiRNA.[@bib29]^,^[@bib46]^,^[@bib49]^,^[@bib57], [@bib58], [@bib59], [@bib60] Interestingly, we also identified two microRNAs, *miR-4482* and *miR-10527*, that were predicted to target *LNC-HC* and were significantly reduced in HCC tumors. Previous studies have not reported these two microRNAs in relationship to cancer development. In Huh7 cells, *miR-183* significantly promoted cell growth; *LNC-HC* overexpression strongly eliminated this effect. In LO2 cells, *LNC-HC* overexpression resulted in no changes in cell proliferation compared with the control group during 72 h; however, it significantly suppressed cell proliferation compared with the *miR-183*-transfected ^overNC^LO2 group. This difference between Huh7 and LO2 cells may due to the fact that the LO2 cells had a slower proliferation rate and transformed into a carcinoma cell type when *miR-183* was overexpressed; under this condition, the tumor suppressor function of *LNC-HC* was obvious.

Furthermore, we also explored the *LNC-HC*/*miR-183* ceRNA pathway in regulating downstream tumor repressors. As a novel gene, it is difficult to analyze the correlation between *LNC-HC* expression and patient survival with liver cancer. We thereupon checked its target genes, including *AKAP12*, *DYRK2*, *FOXN3*, *FOXO1*, and *LATS2*, and the HCC patient survival rate by using the public RNA sequencing (RNA-seq) database Kaplan-Meier Plotter. Except for *DYRK2*, the high mRNA levels of *AKAP12*, *FOXN3*, *FOXO1*, and *LATS2* predicted the longer patient survival. This is in accordance with the results shown in [Figure 6](#fig6){ref-type="fig"}, *LNC-HC/miR-183* coregulate the four genes in Huh7 cells; *DYRK2* could be controlled only in LO2 cells. The discrepancy of *DYRK2* suggests a potential variation during cancer pathogenesis. Supposing that *DYRK2* overexpression is a compensatory effect induced by a high degree of malignancy, it could be explained that decreased *DYRK2* predicts longer patient survival. However, one existing study reported that depletion of *DYRK2* promoted HCC cell proliferation.[@bib61] This group further showed that a low expression of *DYRK2* predicted a poor prognosis for HCC patients (n = 86). Due to the above contradiction, more studies need to be conducted to detail the function and expression pattern of *DYRK2* during HCC pathogenesis. *AKAP12* and *FOXN3* have been reported to be decreased in HCC tissues compared to adjacent hepatic tissues and to function as tumor suppressors.[@bib20]^,^[@bib62], [@bib63], [@bib64] In our study, *AKAP12* and *FOXN3* were verified to be correlated with *LNC-HC* expression in HCC tumors but not in paired-adjacent and normal samples. These observations suggested that the function of *LNC-HC* was different under different conditions, such as normal and carcinogenic treatments. *LATS2* is an influential molecule with strong antitumor effects. It play roles in mitochondrial function and the Wnt/β-catenin pathway,[@bib65] AMPK-Mfn2 pathway,[@bib66] EMT,[@bib67]^,^[@bib68] Hippo pathway[@bib69]^,^[@bib70] and the YAP/TAZ system.[@bib71], [@bib72], [@bib73] Here, *LATS2* was strongly correlated with *LNC-HC* not only in tumors and adjacent liver tissues, but also in all samples containing tumor, adjacent tissue, and normal liver tissue. When combined, the results of correlation analysis with the MTT, colony formation, and wound healing assays under LNC-HC overexpression and target gene knockdown, it could be concluded that the *LNC-HC/ miR-183/FOXN3* and *LATS2* pathways play a vital role in HCC cell proliferation and HCC pathology.

Overall, we identified *LNC-HC* as a novel human lncRNA and described its antitumor function in HCC. The identification of *LNC-HC* not only reveals new regulatory pathways important for understanding HCC pathology, but it also provides new insights into therapeutic possibilities for the prevention and treatment of HCC.

Materials and Methods {#sec4}
=====================

SMART RACE {#sec4.1}
----------

The human homologous nucleotide fragment of rat *lnc-HC* was obtained through a BLAST search of the UCSC database. Then, 5′- and 3′-RACE of *LNC-HC* were conducted using the BD SMART RACE cDNA amplification kit (Clontech Laboratories, Mountain View, CA, USA) according to the manufacturer's instructions. The primers used for 5′-RACE of *LNC-HC* were 5′-CTCCCAACCTAAGTTTCCGTTCCTCA-3′ (5-GSP) and 5′-CGTTCCTCATTTCCACTTGCCTCAGA-3′ (5-NGSP). The primers used for 3′-RACE of *LNC-HC* were 5′-AATCACAGAGCCAGAAGCCAGAGGG-3′ (3-GSP) and 5′-GAGGCAAGTGGAAATGAGGAACGG-3′ (3-NGSP).

Bioinformatics Analysis {#sec4.2}
-----------------------

The ORF prediction of *LNC-HC* was conducted using the ORF Finder online software (<https://www.ncbi.nlm.nih.gov/orffinder/>). The predicted *LNC-HC* ORFs are depicted in [Table S2](#mmc1){ref-type="supplementary-material"}. The conserved protein domains were verified by comparison to the predicted *LNC-HC* ORFs obtained from a protein BLAST search (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>) of the nonredundant protein sequences (nr) and reference proteins (refseq_protein) databases. The translation potential of *LNC-HC* was determined with a coding potential calculator (<http://cpc2.cbi.pku.edu.cn/>).

Northern Blotting {#sec4.3}
-----------------

Northern blotting analysis was performed by using total RNA (30 μg) from the LO2 cell line, with digoxigenin (DIG)-labeling *SLC25A15*-probe or *LNC-HC*-probe. Detection was conducted with the DIG-High Prime DNA labeling and detection starter kit II (Roche, Basel, Switzerland), according to the manufacturer's instructions. The primers used for the *SLC25A15* DIG-labeling probe are 5′-TCCAATCCTGCTATCCAGGC-3′ and 5′-CCGGCTCAGTTCATAGCCAC-3′, and for *LNC-HC* the DIG-labeling probe are 5′-AGTGTTCCTAAGCAGCCTGT-3′ and 5′-TTCCTCATTTCCACTTGCC-3′.

Construction of EGFP/FLAG Fusion Protein Expression Vectors and Protein Expression Assay {#sec4.4}
----------------------------------------------------------------------------------------

The C-terminal EGFP and FLAG tag were inserted into the pcDNA3.1+ vector between the *Eco*RI and *Xho*I restriction sites ([Figure S1](#mmc1){ref-type="supplementary-material"}). Then, the predicted ORF1--3 of *LNC-HC* (from the transcription start site to the end of ORFs without a stop codon) was inserted into the pcDNA3.1-EGFP/FLAG vector between the *Bam*HI and *Eco*RI sites. The first exon sequence of protein-coding gene *ACTB* (171 bp, 48 bp before the ATG start codon and without a stop codon) was the control of the protein coding gene. *Lnc-DC* (621 bp, full-length sequence, without a stop codon) was the control of lncRNAs. The primers for amplifying target sequence are shown in [Table S3](#mmc1){ref-type="supplementary-material"}. These vectors were transfected into LO2 cells separately with Lipofectamine 2000 (Invitrogen, Waltham, MA, USA), according to the manufacturer's instructions. After 48 h, FLAG-tag plasmid-transfected cells were collected for immunoblotting, whereas EGFP-tag plasmid-transfected cells were visualized by fluorescence microscopy (Olympus, Tokyo, Japan). To detect the FLAG-tag fusion protein expression, cell lysates were loaded in nitrocellulose (NC) membrane at the indicated level (2, 1.75, 1.5, 1.25, 1, 0.75, and 0.5 μg). GAPDH (10 μg of protein from each group of cells) was the loading control. Mouse anti-FLAG antibody (CMCTAG, Shanghai, China) and mouse anti-GAPDH antibody (CMCTAG, Shanghai, China) were the primary antibodies.

Clinical Samples and Cell Lines {#sec4.5}
-------------------------------

Twenty hepatic tumor tissues, 20 paired adjacent non-tumor tissues, and 10 paired normal tissues were obtained from patients with HCC who underwent surgical treatment at The First Affiliated Hospital of Xi'an Jiaotong University (Xi'an, China). Adjacent non-tumor tissues were defined as tissues \>1 cm and \<5 cm from the tumor boundary. Normal tissues were defined as tissues \>5 cm from the tumor boundary. Signed informed consents were collected and the study was approved by the Ethics Committee of The First Affiliated Hospital of Xi'an Jiaotong University. LO2 cells were maintained in RPMI 1640 medium (HyClone, South Logan, UT, USA) containing 10% fetal bovine serum (FBS) (ExCell Bio, Shanghai, China). Huh7 cells were maintained in DMEM high-glucose medium (HyClone, South Logan, UT, USA) supplemented with 10% FBS (ExCell Bio, Shanghai, China).

RNA Isolation and Quantitative Real-Time PCR {#sec4.6}
--------------------------------------------

Total RNA was isolated from stored HCC liver samples, LO2 cells, and Huh7 cells. RNA was extracted using TRIzol reagent (Invitrogen, Waltham, MA, USA). The extraction was performed with the chloroform-isopropanol method. RNA quality and concentration were measured using a NanoDrop instrument. cDNAs were generated by the reverse transcription of mRNAs with 5 μg of total RNA per sample using the RevertAid first-strand cDNA synthesis kit (Thermo Fisher Scientific, Waltham, MA, USA). The microRNA cDNAs were reverse transcribed with 2 μg of total RNA per sample using a Mir-X miRNA qRT-PCR SYBR kit (Clontech Laboratories, Mountain View, CA, USA). Quantitative real-time PCR was performed using SYBR Green qPCR master mix (Roche, Basel, Switzerland) in an Agilent Mx3005P instrument. Primer information for the mRNA quantitative real-time PCR is shown in [Table S4](#mmc1){ref-type="supplementary-material"}. Primer information for the microRNA quantitative real-time PCR is shown in [Table S5](#mmc1){ref-type="supplementary-material"}.

Western Blotting {#sec4.7}
----------------

Protein was isolated from cells by using cell lysis buffer (Beyotime Biotechnology, Shanghai, China). Protein from different cells were separated by 8% SDS-PAGE gel and transferred onto a polyvinylidene fluoride (PVDF) membrane (Bio-Rad, Hercules, CA, USA) according to the standard process. Protein expression was analyzed by using rabbit anti-ACTB antibody (Santa Cruz Biotechnology, Shanghai, China, 1:500), mouse anti-GAPDH antibody (CMCTAG, Shanghai, China), rabbit anti-AKAP12 antibody (Proteintech, Wuhan, Hubei, China, 1:1,000), mouse anti-DYRK2 antibody (R&D Systems, Minneapolis, MN, USA, 1:1,000), rabbit anti-FOXN3 antibody (Abcam, Cambridge, MA, USA, 1:1,000), rabbit anti-FOXO1 antibody (Proteintech, Wuhan, Hubei, China, 1:1,000), and rabbit anti-LATS2 antibody (Proteintech, Wuhan, Hubei, China, 1:1,000).

Gene Overexpression and Knockdown {#sec4.8}
---------------------------------

The expression vectors were constructed first. Full-length *LNC-HC* was obtained by PCR with PrimeSTAR GXL DNA polymerase (Takara Bio, Beijing, China) and inserted into the pcDNA3.1+ vector between the *Eco*RI and *Xho*I sites to obtain pcLNC-HC; the *SLC25A15* coding region was inserted into the pcDNA3.1+ vector between *Hin*dIII and *Bam*HI sites to obtain pcSLC25A15. The primers are shown in [Table S6](#mmc1){ref-type="supplementary-material"}. For gene knockdown, short hairpin RNAs (shRNAs) for *LNC-HC* and *SLC25A15* knockdown were ordered from GenePharma (Shanghai, China). The target sequences of the *LNC-HC* shRNAs and the *SLC25A15* shRNAs are shown in [Table S6](#mmc1){ref-type="supplementary-material"}. After the transfection of pcDNA3.1+, pcLNC-HC, pcSLC25A15, NC shRNAs, *LNC-HC* shRNAs, and *SLC25A15* shRNAs using Lipofectamine 2000 (Invitrogen, Waltham, CA, USA) for 24 h, LO2 and Huh7 cells were treated with G418 (600 μg/mL in LO2 and 800 μg/mL in Huh7) for a period of 30 days to select the stable cell lines ^overNC^LO2/Huh7, ^overLNC-HC^LO2/Huh7, ^overSLC25A15^LO2/Huh7, ^NCshR^LO2/Huh7, ^LNC-HCshR^LO2/Huh7, and ^SLC25A15shR^LO2/Huh7, respectively.

Cell Proliferation Assay {#sec4.9}
------------------------

An MTT assay was used to measure cell proliferation. In detail, 1 × 10^4^ Huh7 or LO2 cells were seeded per well in a 96-well plate. The cells were transfected with the NC mimic (50 nM) or *miR-183* mimic (50 nM) by using Lipofectamine RNA iMAX reagent (Invitrogen, Waltham, CA, USA) and the pcDNA3.1+ or pcLNC-HC vector by using Lipofectamine 2000 reagent (Invitrogen, Waltham, CA, USA) according to the manufacturer's instructions. To check the cooperative effect of LNC-HC overexpression and knockdown of its target genes, Huh7 cells were transfected with pcDNA3.1+ or pcLNC-HC vector and NC siRNA (50 nM) or the indicated siRNA (50 nM). At different time points (0, 24, 48, and 72 h) the cells were incubated with 0.5 mg/mL MTT solution at 37°C for 4 h. Then, the culture medium was changed to DMSO (150 μL per well). The optical absorbance was measured at a wavelength of 450 nm. The sequence information for the *miR-183* mimic, NC mimic, siRNAs targeting *AKAP12*, *FOXN3*, *FOXO1*, and *LATS2* and NC siRNA are shown in [Table S7](#mmc1){ref-type="supplementary-material"}. The siRNAs were ordered from Genepharma (Shanghai, China).

Mouse Xenograft Tumor Model {#sec4.10}
---------------------------

Animal experiments were approved by the Institutional Animal Ethics Committee of the Xi'an Jiaotong University School of Medicine (permission ID XJ2006Y039; Xi'an Jiaotong University, Xi'an, China) and were conducted in accordance with the European Communities Council Directive 2010/63/EU for the protection of animals used for scientific purposes. Male BALB/c nude mice (n = 6, aged 4 weeks) were ordered from the Medical Experimental Animal Center, Xi'an Jiaotong University. For the xenograft tumor model, 5 × 10^6\ overNC^Huh7 or ^overLNC-HC^Huh7 cells were subcutaneously injected into the left or right flanks of nude mice on day 1. After 5 days, the tumor volume and body weight were detected every 5 days. On day 45, the mice were sacrificed, and the tumors were collected and measured.

Dual-Luciferase Reporter Gene Assay {#sec4.11}
-----------------------------------

The *LNC-HC* DNA fragments targeted by *hsa-miR-183-5p* (wild-type and mutant) were ordered from Sangon Biotech (Shanghai, China). They were inserted into the pmirGLO vector between the *Nhe*I and *Xho*I sites to generate pLNC-HC1-WT, pLNC-HC1-mut, pLNC-HC2-WT, and pLNC-HC2-mut. LO2 and Huh7 cells were seeded into 48-well plates and cotransfected with different pLNC-HC-target plasmids (100 ng) and NC/*miR-183* mimic (50 nM) for 24 h. The relative luciferase activity of each cell group was measured using the Dual-luciferase reporter assay system (Promega, Madison, WI, USA) according to the manufacturer's instructions.

Survival Analysis {#sec4.12}
-----------------

The effects of *AKAP12*, *DYRK2*, *FOXN3*, *FOXO1*, and *LATS2* on the overall survival of patients with liver cancer (n = 364) were analyzed by using the online RNA-seq database Kaplan-Meier Plotter (<http://kmplot.com/analysis/>).[@bib74]

Statistical Analysis {#sec4.13}
--------------------

Quantitative data were expressed as the means ± SEM. The statistical analysis of the differences between groups was conducted by using an unpaired Student's t test. The difference in xenograft tumor growth between the ^overNC^Huh7 and ^overLNC-HC^Huh7 injection groups was analyzed by two-way ANOVA. The Fisher's exact test was performed to compare the association between *LNC-HC* expression and clinical parameters. ∗p \< 0.05, ∗∗p \< 0.01, and ∗∗∗p \< 0.001 were considered statistically significant.
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